| CAS NO: | 2113650-04-5 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
| Cas No. | 2113650-04-5 |
| Canonical SMILES | OC[C@@H](NCC1=CC(C)=C(C=C1OCC2=CC=CC(C#N)=C2)OCC3=CC=CC(C4=CC=C5OCCOC5=C4)=C3C)C(O)=O.[H]Cl |
| 分子式 | C35H35ClN2O7 |
| 分子量 | 631.11 |
| 溶解度 | DMSO: 12.5 mg/mL (19.81 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cells[1]. BMS-1001 binds to human PD-L1 and blocks its interaction with PD-1. BMS-1001 presents low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes[1]. [1]. Skalniak L, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8(42):72167-72181. |
m.cnreagent.com